- Section 2: Testing and Assessment
- Initial History
- Initial Physical Examination
- Initial and Interim Laboratory and Other Tests
- Interim History and Physical Examination
- HIV Classification: CDC and WHO Staging Systems
- CD4 and Viral Load Monitoring
- Risk of HIV Progression/Indications for ART
- Early HIV Infection
- Expedited HIV Testing
- Resistance Testing
- Karnofsky Performance Scale
- Occupational Postexposure Prophylaxis
- Nonoccupational Postexposure Prophylaxis
- Preventing HIV Transmission/Prevention with Positives
- Immunizations for HIV-Infected Adults and Adolescents
- Preventing Exposure to Opportunistic and Other Infections
- Opportunistic Infection Prophylaxis
- Latent Tuberculosis Infection
- Smoking Cessation
- Abnormalities of Body-Fat Distribution
- Insulin Resistance, Hyperglycemia, and Diabetes on Antiretroviral Therapy
- Coronary Heart Disease Risk
- Renal Disease
- Immune Reconstitution Inflammatory Syndrome
- Anal Dysplasia
- Candidiasis, Oral and Esophageal
- Candidiasis, Vulvovaginal
- Cervical Dysplasia
- Cryptococcal Disease
- Cytomegalovirus Disease
- Gonorrhea and Chlamydia
- Hepatitis B Infection
- Hepatitis C Infection
- Herpes Simplex, Mucocutaneous
- Herpes Zoster/Shingles
- Kaposi Sarcoma
- Molluscum Contagiosum
- Mycobacterium avium Complex Disease
- Mycobacterium tuberculosis
- Pelvic Inflammatory Disease
- Pneumocystis Pneumonia
- Progressive Multifocal Leukoencephalopathy
- Seborrheic Dermatitis
Publish date: April 2014
Precancerous lesions and cancer of the cervix are associated with human papillomavirus (HPV), a sexually transmitted virus. Carcinogenic strains of HPV, in conjunction with other factors, may cause dysplasia and cancer not only of the cervix, but also of the vulva, vagina, anus, and oropharynx. HIV-infected women have a higher prevalence of HPV infection than do HIV-uninfected women, and a higher prevalence of oncogenic HPV types. They are about 10 times more likely to develop cervical dysplasia, or intraepithelial neoplasia (CIN), precursors to cervical cancer. Unfortunately, they also have a higher risk of invasive cervical cancer and tend to have more aggressive forms of cervical cancer and poorer responses to treatment. Invasive cervical cancer is an AIDS-defining illness.
The risk of high-grade cervical lesions and cervical cancer appears to be higher for women with advanced immunodeficiency than for women with preserved CD4 cell counts. Other risk factors for dysplasia and cervical cancer include African-American ethnicity, a history of smoking, younger age at onset of sexual intercourse, and multiple sex partners. Effective antiretroviral therapy (ART) with immune reconstitution has not been shown to prevent the progression of CIN.
Screening for cervical cancer and appropriate intervention in women with high-grade CIN (CIN 3) are effective in preventing cervical cancer. Frequent monitoring and careful follow-up in women with low-grade lesions are essential for preventing progression to invasive disease. For all HIV-infected women (if they have had sex partners), including adolescents and young women, Papanicolaou (Pap) testing should be performed routinely. An initial test should be done at the time of HIV diagnosis, repeated 6 months after the first test, then performed annually thereafter if the results are normal. (see chapter Initial and Interim Laboratory and Other Tests.)
Because the risk of anal dysplasia also is increased among HIV-infected women (in some studies, rates of anal dysplasia were higher than rates of cervical dysplasia), many experts and some guidelines recommend concurrent screening for anal dysplasia. For further information, see chapter Anal Dysplasia.
For information on prevention of HPV infection, see "Prevention," below.
Patients with CIN or early cervical cancer usually are asymptomatic, and disease will not be diagnosed unless screening is performed. Genital condylomata (warts) indicate infection with HPV and typically are associated with low-risk types of HPV; however, a mixture of HPV types may be present, and women with genital warts may have concurrent dysplasia.
The classic symptom of early invasive cervical neoplasia is intermittent, painless bleeding between menstrual periods, which may present initially as postcoital spotting. Late symptoms of invasive cervical carcinoma include flank and leg pain, dysuria, hematuria, rectal bleeding, and obstipation.
Ask all female patients about risk factors for, previous history of, and preventive measures against cervical dysplasia and cancer, including the following:
- Genital warts; previous or current HPV infection
- Previous abnormal cervical Pap test result
- Previous abnormal anal Pap test result
- Previous cervical cancer; when and how treated
- Sexual activity before age 20
- History of multiple sex partners
- Cigarette smoking
- CD4 count of <200 cells/µL
- Oral contraceptive use
- History of HPV vaccination
Perform a focused examination of the abdomen and pelvis. Examine the external genital and perianal region. Perform speculum and bimanual examinations to evaluate the vagina and cervix. Look for lesions, masses, warts, and cervical inflammation or discharge, as well as exophytic or ulcerative cervical lesions with or without bleeding. Note that simple visual examination may not reveal abnormalities.
HIV-infected women have an increased risk of cervical dysplasia with progression to cervical cancer. If abnormalities of cervical disease are suspected, an appropriate evaluation should be performed. Because most women with CIN have no symptoms, routine screening should be performed for all women.
Perform Pap screening for all HIV-infected women. The initial test should be conducted at the time of HIV diagnosis, a second (if the first is normal) should be performed 6 months later. Screening should be repeated annually thereafter throughout life if all results are normal. (For HIV-uninfected adolescents and young women, recent guidelines recommend beginning cervical screening at age 21; for HIV-infected young women, guidelines suggest screening beginning within 1 year of first sexual activity, given the risk of progression of cervical abnormalities.) If a Pap result is abnormal, see below. Also consider screening for anal dysplasia with an anal Pap test (see chapter Anal Dysplasia).
Cervical (and anal) cytology usually is graded using the Bethesda 2001 system (see "References," below), which categorizes disease in increasing order of severity as follows:
- Negative for intraepithelial lesion or malignancy
- Atypical squamous cells of undetermined significance (ASCUS)
- Atypical squamous cells, cannot exclude HSIL (ASC-H)
- Low-grade squamous intraepithelial lesion (LSIL)
- High-grade squamous intraepithelial lesion (HSIL)
- Squamous cell carcinoma (SCC)
Other abnormalities may be noted, including the following:
- Atypical glandular cells (AGCs), including the following subcategories:
- AGC not otherwise specified (AGC NOS) (includes endocervical, endometrial, or glandular cells)
- AGC, favor neoplasia (includes endometrial or glandular cells)
- AIS (endocervical adenocarcinoma in situ)
- Infectious organisms such as Trichomonas
Evaluation of Cytologic Abnormalities
Atypical squamous cells of undetermined significance
If ASCUS is present without inflammation or suspected neoplastic process, several options for management exist.
- Most experts recommend that all women with ASCUS be referred for colposcopy and directed biopsy, regardless of their degree of immunodeficiency. If the biopsy result shows no dysplasia (and the examination is adequate), the patient should be monitored by annual Pap tests.
- As an alternative, patients who are considered reliable for follow-up may repeat the Pap test in 6-12 months. If repeat Pap is reported at greater than ASCUS, the woman should be referred for colposcopy.
- There are limited and conflicting data to support the use of HPV DNA testing as part of the management of HIV-infected women with ASCUS. Current OI guidelines (see "References," below) emphasize that HPV testing alone is not recommended.
Atypical squamous cells, cannot exclude HSIL
Women with abnormalities suggestive of high-grade dysplasia should be referred for colposcopy.
Low-grade squamous intraepithelial lesion
Women with LSIL should be referred for colposcopy and directed biopsy.
High-grade squamous intraepithelial lesion or squamous cell carcinoma
Women with HSIL are at high risk of high-grade intraepithelial neoplasia or cervical cancer and should undergo colposcopy with endocervical assessment and directed biopsy as soon as possible. Refer to an oncology specialist for treatment.
Atypical glandular cells
Because of the high rate of significant lesions in patients with AGS, colposcopy with endocervical sampling is recommended for all subcategories, including AIS. In women over age 35, endometrial sampling is recommended in addition to colposcopy and endocervical sampling. Refer to an appropriate specialist for evaluation.
The optimal management of precancerous cervical lesions has not been identified clearly for all classes of CIN. Consult with an HIV-experienced gynecologist, oncologist, or other dysplasia specialist. High-grade lesions in women with satisfactory colposcopy are typically treated with ablation (e.g., cryo-therapy, electrocautery, laser vaporization) or excision (e.g., loop electrosurgical excision [LEEP], laser or cold-knife conization). For women with unsatisfactory colposcopy, excisional methods are recommended.
Latex or plastic barriers may block transmission of HPV in areas covered by these barriers and have been shown to reduce the risk of infection with oncogenic HPV. Although infection may occur through bodily contact outside the area covered by the barriers, the use of condoms is recommended to prevent transmission or acquisition of HPV (as well as HIV and other STDs).
Two vaccines have been approved by the U.S. Food and Drug Administration for the prevention of certain HPV strains; these are recommended for HIV-infected women and girls 9-26 years of age. They have been shown to reduce rates of cervical dysplasia; the quadrivalent vaccine also has been shown to protect against vulvar, vaginal, and anal dysplasia (as well as anogenital warts) related to the covered HPV types.
- Quadrivalent (Gardasil): includes HPV types 16 and 18 (which cause nearly 70% of cervical cancer, as well as vaginal, vulvar, and anal cancer), and types 6 and 11 (which cause most anogenital warts
- Bivalent (Cervarix): includes HPV types 16 and 18
The quadrivalent vaccine also is recommended for use with males aged 9-26 for prevention of genital warts and anal intraepithelial neoplasia.
These vaccines are not effective against HPV types other than those covered by the vaccine, and they may not be protective against a covered type to which a patient has been exposed previously. For optimal protection, these vaccines should be given before the individual is exposed to HPV through sexual activity. They are likely to be less effective in older adolescents and adults who already may have been infected with one or more of the covered HPV types. There are few data on the use of the vaccines in persons older than 26, and they are not approved for this group. Importantly, women who have been vaccinated should continue to be screened for cervical cancer as described above; vaccination does not protect women perfectly from all oncogenic HPV viruses.
- Recommend the use of latex or polyurethane male or female condoms for vaginal or anal intercourse and plastic or latex barriers for oral sex to reduce the risk of transmitting HPV (the usual cause of cervical cancer) to partners. Barriers also reduce the risk of exposure to other sexually transmitted pathogens.
- Patients who smoke should be advised to quit. Cigarette smoking appears to heighten the risk of cervical cancer and makes HPV more difficult to treat. Discuss options for smoking cessation (see chapter Smoking Cessation), and refer patients to the American Lung Association if local programs are available.
- Emphasize the importance of keeping follow-up appointments for Pap screening or colposcopy to allow early detection of precancerous lesions and appropriate monitoring of abnormalities.
- For women with dysplasia who require treatment, emphasize that early treatment is essential for managing the disease and preventing the development of cancer. Advise patients to keep all medical appointments.
- Aberg JA, Gallant JE, Ghanem KG et al.; HIV Medicine Association of the Infectious Diseases Society of America. Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jan;58(1):e1-e34.
- American Congress of Obstetricians and Gynecologists Committee on Practice Bulletins - Gynecology. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol. 2012 Nov;120(5):1222-38.
- Massad LS, Ahdieh L, Benning L, et al. Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):432-42.
- Massad LS, Einstein MH, Huh WK, et al.; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S1-S27.
- Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed December 1, 2013.
- Solomon D, Davey D, Kruman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002 Apr 24;287(16):2114-9.
- U.S. Department of Health and Human Services. A Guide to the Clinical Care of Women with HIV - 2013 Edition. Rockville, MD: U.S. Department of Health and Human Services; 2013. Accessed March 1, 2013.
Search the Clinical Guide
Abbreviations for Dosing Terminology
- twice daily
- twice weekly
- intramuscular (injection), intramuscularly
- intravenous (injection), intravenously
- oral, orally
- Q2H, Q4H, etc.
- every 2 hours, every 4 hours, etc.
- every morning
- once daily
- every hour
- every night at bedtime
- four times daily
- every other day
- every evening
- three times daily
- three times weekly